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Abstract
We present two cases of Behcet's Disease with
severe eye problems along with oral and genital ulcerations.
Both cases, initially were treated with steroids and oral
immunosuppressive agents, but did not show a response and
ocular disease became worse. Both the cases were kept on
Infliximab therapy. an immediate positive response with
improvement in vision and symptoms was seen. After initial
infusions the ocular damage in both the cases stopped.
Keywords: Behcet's disease, Ocular disease, Uveitis,
Infliximab, Anti TNF-alpha drugs.
Introduction
Behçet's Disease (BD) is rare chronic multisystem
immune-mediated inflammatory disorder, characterized by
recurrent oral and genital mucocutaneous ulcerations with
articular, neurological, gastrointestinal and
ophthalmological and neurological disease involvement.
Ocular involvement presents as bilateral non granulomatous
panuveitis, retinal and choroidal vasculitis, optic neuritis
and retinal vascular occlusion. Although, BD has a
worldwide distribution, it is rare in North American
population and Europe. Prevalence is higher in Turkey,
Middle and Far East region, affecting mainly young adults,
having more severe vascular complications.1
According to the International Study Group criteria,
the diagnosis of BD requires the presence of recurrent oral
ulceration along with any two conditions: recurrent genital
ulceration, eye lesions, skin lesions or a positive skin test.
The diagnosis is clinical because there is no specific
evidence, pathognomonic symptoms or specific laboratory
findings.1
Behçet's entails recurrent attacks of acute
inflammation and generally, does not run a chronic
persistent course. Involvement of gastrointestinal tract,
central nervous system, and large vessels is occasional,
and can be life-threatening.1 The most feared
complication of BD is irreversible vision loss.
Susceptibility to BD is associated with HLA-B51 allele.
Environmental factors such as infectious agents have
been implicated in its pathogenesis. 
Corticosteroids and immunosuppressants are the
mainstay for treating this disease, however, an increasing
number of refractory cases occur. Recently, Infliximab and
other tumour necrosis factor inhibitors have shown dramatic
results in treating various manifestations of BD. 
Case Presentation
Case-1:
A 23-year male, presented with history of recurrent
ulcers in mouth and genital tract, blurring of vision and
arthralgias, since one year. The patient had apthous ulcers
in the mouth, on glans penis and scrotum. He also
complained of occasional redness in the eyes along with
gradual decrease in vision and arthralgias. A diagnosis of
BD was made. On eye examination patient was found to
have a low visual acuity (V/A). The left eye had a V/A of
20/400 while right eye V/A was worse at, "counting fingers
at 2 feet" secondary to severe panuveitis. The IOP was
normal at 14 mmHg bilaterally. ESR was 51, CRP was high
23. He was kept on Prednisolone and Azathioprine. In the
next few months, his follow up visits showed worsening
V/A secondary to repeated attacks of uveitis in both eyes
despite getting Azathioprine, three bilateral intraocular
injections of Bevacizumab and, systemic as well as
intraocular steroids. The patient's V/A detoriated further
during therapy, patient had "Perception of Light" bilaterally
a month ago, before referral to Rheumatology clinic. He
was then switched to Infliximab therapy. An immediate
effect was seen after the first dose leading to stabilized
vision. He received three doses of Infliximab over a period
of seven months (total time for his treatment at AKU was
two years) until his uveitis attacks got settled. Patient's V/A
improved to "Counting Fingers at 4 feet" bilaterally, he was
continued on Azathioprine and low dose Steroids for
maintenance therapy. 
Case-2:
A 29-year-old male presented with history of
recurrent oral and genital ulcers, vision problems and low
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grade fever for few months. His major complaint was
decreased vision with redness and pain in both eyes. On
examination, the patient had numerous apthous ulcers in the
mouth and on glans penis. Eye exam showed diffuse
anterior uveitis and V/A of "counting fingers at 2 feet" and
"20/400" in right and left eye, respectively. The IOP was
measured to be at 18 mmHg (within normal range of 10-21
mmHg). Diagnosis of BD was made. His ESR was 62, CRP
was 12 and a positive ANA was present. Oral steroids with
Azathioprine were started. Despite high dose therapy for a
few months, his V/A continued to deteriorate with relapses
of anterior uveitis. He was then started on intravenous
Infliximab therapy. After the first two doses the intensity of
ocular inflammation weaned off gradually. However, after
the second dose of Infliximab, the patient developed
reactivation of pulmonary Tuberculosis thus the drug was
withheld. Confirmed by a Purified protein derivative (PPD)
test and a chest radiograph, acute tuberculous treatment
(ATT) was given for 6 months. He recovered from
pulmonary tuberculosis successfully, Infliximab was then
started. Patient's Intraoccular pressure (IOP) remained at
baseline 18 mmHg throughout his treatment. Patient's right
eye vision was lost due to recurrent attacks of Uveitis and
retinal vasculitis, however, the left eye vision (V/A 20/400)
has been sustained after treatment with Infliximab. 
Discussion
BD was first depicted in 1937 by a Turkish
dermatologist named Hulusi Behçet. Behçet referred to BD
as a "complex of recurrent oral ulcers, genital sores, and
hypopyon uveitis that could lead to blindness."2 Ocular
involvement of BD, which is basically in the form of
anterior and posterior uveitis, cataracts, conjunctivitis or
retinal vasculitis, is the most feared symptom of the disease.
Eye inflammation, which occurs in 70% of cases,1 is
considered one of the major criteria upon which the
diagnosis is based. The ocular disease is characterized by
repetitive and explosive inflammatory attacks, which can
subside spontaneously or with treatment. Disease affecting
the back of eye, is sight threatening, may produce macular
oedema, retinal swelling and haemorrhage, and
inflammation of blood vessels. Despite therapeutic
intervention, about 25% of people with ocular lesion
become blind.3 Early age of onset and male gender are bad
prognostic factors for ocular disease.4 In a study of BD,
ocular disease was bilateral in 78.1% and panuveitis was the
most common finding. Risk of losing vision within 10 years
was 30% for men and 17% for women.5
Corticosteroids and immunosuppressants have been
the drugs of choice for BD. Topical mydriatic agents and
corticosteroids are used initially for mild disease with
recurrences if steroids are used as a monotherapy. Trials
have shown that Azathioprine and Cyclosporine, Colchicine
are effective for treatment of Behcets uveitis.6,7
Recent advances in medical treatment of BD have
shown TNF-Alpha inhibitors as a new effective drug.8,9
Infliximab, a chimeric monoclonal antibody to TNF-α, was
initially developed to treat systemic inflammatory disorders
such as rheumatoid arthritis and Crohn's disease. Levels of
TNF-α (as well as other pro inflammatory cytokines) are
elevated in active BD thereby suggesting that anti-TNF-α
therapy is valuable. Clinically, significant improvement of
various BD manifestations with infliximab therapy, and
other Anti-TNF therapies, has been reported in literature.9
Biologics like Infliximab have successfully been
reported to treat resistant Neuro- Bechets disease, eye
threatening panuveitis and severe mucocutaneous
lesions.8,10 The success of this drug in treating acute uveitis
in patients with BD is secondary to high serum levels the
drug can achieve. A Japanese study of relationship between
serum Infliximab levels and acute uveitis, done in 2010,
concluded that serum concentration of Infliximab in each
patient was significantly correlated with its effectiveness in
settling recurrent episodes of uveitis.11 An Open Label Trial
conducted recently, showed that infliximab is effective in
suppressing the occurrence of uveitis attacks and also has a
significant corticosteroid sparing effect.12
Here, we reported two cases of severe Bechets eye
disease treated successfully with Infliximab.
Despite one of our patients developing reactivation
of Pulmonary Tuberculosis after second Infliximab was
withheld and resumed after 6 months, which was the
duration for which ATT was given.
Conclusion
BD can be incapacitating if not treated aggressively,
its complications, include complete blindness. There is a
severe need to assess patients by a multi-disciplinary team
to start and adjust therapy on time to prevent complications.
As per our reports, Infliximab is an effective therapeutic
choice for steroid and other immunosuppressant resistant
ocular involvement of BD. 
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